The weekly litigation news digest is live. Subscribe now

IP Verse

Chemically Modified Single-Stranded Rna-Editing Oligonucleotides - EP3507366

The patent EP3507366 was granted to Proqr Therapeutics II on Oct 7, 2020. The application was filed on Aug 31, 2017 under application number EP17771348A. The patent is currently recorded with a legal status of "Granted And Under Opposition".

EP3507366

PROQR THERAPEUTICS II
Application Number
EP17771348A
Filing Date
Aug 31, 2017
Status
Granted And Under Opposition
Sep 4, 2020
Publication Date
Oct 7, 2020
External Links
Slate, Register, Google Patents

Patent Summary

Patent Family

Patent Family

Patent Oppositions

Patent oppositions filed by competitors challenge the validity of a granted patent. These oppositions are typically based on claims of prior art, lack of novelty, or non-obviousness. They are a key part of the process for determining a patent's strength and enforceability.

CompanyOpposition DateRepresentativeOpposition Status
MARGARET DIXONJun 25, 2021MAIWALDADMISSIBLE

Patent Citations (11) New

Patent citations refer to prior patents cited during different phases such as opposition or international search.

Citation PhasePublication Number
DESCRIPTIONGB20170000939
DESCRIPTIONWO2017EP65467
DESCRIPTIONWO2016097212
INTERNATIONAL-SEARCH-REPORTWO2014011053
INTERNATIONAL-SEARCH-REPORTWO2016097212
OPPOSITIONUS8372816
OPPOSITIONUS9650627
OPPOSITIONUS9732347
OPPOSITIONWO2011085271
OPPOSITIONWO2016097212
OPPOSITIONWO2017220751

Dossier Documents

The dossier documents provide a comprehensive record of the patent's prosecution history - including filings, correspondence, and decisions made by patent offices - and are crucial for understanding the patent's legal journey and any challenges it may have faced during examination.

  • Date

    Description

  • Get instant alerts for new documents